Revolution Medicines Inc (RVMD)
$46.43 -$0.43 (-0.91%) 4:38 PM 12/11/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$8.88B -
Day's Range
$46.78 - $47.53 -
Volume
2,332,948 -
52 Week Low / High
$23.51 - $62.40 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 10
- Strong Buy
- 5
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong Sell
- $36.00
- Target Price
Company News
-
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast — Oct 7th, 2024
Revolution Medicines, Inc. Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWS...
-
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast — Oct 7th, 2024
Revolution Medicines, Inc. Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWS...
-
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast — Oct 7th, 2024
Revolution Medicines, Inc. Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWS...
-
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast — Oct 7th, 2024
Revolution Medicines, Inc. Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWS...
-
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast — Oct 7th, 2024
Revolution Medicines, Inc. Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWS...
-
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast — Oct 7th, 2024
Revolution Medicines, Inc. Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWS...
-
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast — Oct 7th, 2024
Revolution Medicines, Inc. Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWS...
-
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast — Oct 7th, 2024
Revolution Medicines, Inc. Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWS...
-
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast — Oct 7th, 2024
Revolution Medicines, Inc. Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWS...
Portfolio
Comprised of 1 portfolios